Vinva Investment Management Ltd Grows Holdings in Becton, Dickinson and Company $BDX

Vinva Investment Management Ltd increased its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 16.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 16,954 shares of the medical instruments supplier’s stock after purchasing an additional 2,396 shares during the period. Vinva Investment Management Ltd’s holdings in Becton, Dickinson and Company were worth $2,897,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of BDX. Bill Few Associates Inc. boosted its stake in shares of Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 55 shares during the period. Gilbert & Cook Inc. raised its stake in Becton, Dickinson and Company by 2.0% during the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after acquiring an additional 56 shares during the last quarter. Mendel Money Management lifted its position in Becton, Dickinson and Company by 2.6% during the 2nd quarter. Mendel Money Management now owns 2,254 shares of the medical instruments supplier’s stock worth $388,000 after acquiring an additional 58 shares during the period. Plancorp LLC grew its stake in shares of Becton, Dickinson and Company by 4.1% in the 1st quarter. Plancorp LLC now owns 1,499 shares of the medical instruments supplier’s stock valued at $343,000 after purchasing an additional 59 shares during the last quarter. Finally, Moody National Bank Trust Division grew its stake in shares of Becton, Dickinson and Company by 2.4% in the 2nd quarter. Moody National Bank Trust Division now owns 2,586 shares of the medical instruments supplier’s stock valued at $445,000 after purchasing an additional 60 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Down 0.8%

Becton, Dickinson and Company stock opened at $193.97 on Friday. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $251.99. The firm has a market capitalization of $55.60 billion, a price-to-earnings ratio of 34.89, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The stock’s fifty day moving average is $187.36 and its two-hundred day moving average is $182.95. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. The business had revenue of $5.32 billion for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. Analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a $1.05 dividend. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Monday, December 8th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 72.04%.

Analyst Ratings Changes

BDX has been the subject of several recent research reports. Stifel Nicolaus decreased their price target on Becton, Dickinson and Company from $224.00 to $210.00 in a report on Friday, November 7th. Jefferies Financial Group cut their price objective on shares of Becton, Dickinson and Company from $257.00 to $215.00 in a research report on Friday, November 7th. Piper Sandler lowered their target price on shares of Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a report on Friday, November 7th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $203.27.

Insider Buying and Selling

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the firm’s stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the completion of the transaction, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Bertram L. Scott sold 217 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $176.58, for a total value of $38,317.86. Following the completion of the transaction, the director directly owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 1,249 shares of company stock valued at $231,358. Corporate insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.